middle.news
Recce’s Inhaled RECCE 327 Slashes Drug-Resistant Pneumonia in Preclinical Tests
9:56am on Wednesday 26th of November, 2025 AEDT
•
Healthcare
Read Story
Recce’s Inhaled RECCE 327 Slashes Drug-Resistant Pneumonia in Preclinical Tests
9:56am on Wednesday 26th of November, 2025 AEDT
Key Points
RECCE 327 shows >99.99% bacterial reduction in lung infections
Effective nebulised delivery overcomes solubility limits of standard antibiotics
Targets critical multidrug-resistant Acinetobacter baumannii in hospital pneumonia
Preclinical data supports inhaled therapy potential in severe pulmonary infections
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE